Latest Drug-Related Developments in Global Dry Eye Disease Market

1
Latest Drug-Related Developments in Global Dry
Eye Disease Market As per a study on the
incidence and prevalence of dry eye disease in
the United States, the dry eye disease (DED)
prevalence was 5.28 overall, with 2.96 male
beneficiaries and 7.78 female beneficiaries.
According to another study on the economic burden
of dry eye disease in the United States, DED
incurred 55.4 billion in costs annually. Our
predictions project that the global eye disease
market growth is estimated to progress at a CAGR
of 5.11 during 23-32 and garner 8884.34 million
by 2032. As a result, drugs designed with
specific DED indications are ushering in a new
era in dry eye disease management.

• This blog focuses on some of the recent strategic
  developments related to dry eye disease drugs.
• OptiLight by Lumenis
• On 29th April 2021, Lumenis Ltd announced the
  grant of FDA approval for its newest intense
  pulsed light (IPL) device.
• Subsequently, Lumenis launched OptiLight, a
  bright solution for dry eyes.
• Intense pulsed light (IPL) therapy is a new
  treatment for rosacea and evaporative dry eye.
  Meibomian gland dysfunction (MGD) increases the
  severity of dry eye disease (DED) and can
  clinically impact the patients quality of life.
  Intense pulsed therapy (IPL) can benefit dry eye
  by enhancing the dysfunction of the meibomian

glands.
2

• OptiLight is patented with Lumenis OPT
  technology and is designed for a controlled,
  precise, and consistent light-based treatment of
  dry eye disease.
• Dr. Steven J. Dell, the lead investigator in the
  Lumenis clinical trial for the FDA and medical
  director of Dell Laser Consultants, said, We
  deal with dry eye every day, but unless we
  address the underlying inflammation, its
  difficult to meaningfully impact the disease.
  OptiLight helps us to address the inflammation,
  as shown in Lumenis IPL clinical trials, and
  improves signs of dry eye disease due to MGD,
  positioning it as a valuable tool in our dry eye
  toolkit. (Source)
• Kala announces to sell INVELTYS and EYSUVIS
• On 23rd May 2022, Kala Pharmaceuticals announced
  its entry into a definitive agreement to sell its
  intellectual property assets and commercial
  portfolio to Alcon Inc. This entails INVELTYS, a
  corticosteroid for treating post-operative pain
  and inflammation following ocular surgery.
  Alongside EYSUVIS, the first and only United
  States Food and Drug Administration
  (FDA)-approved medicine for the short- term
  treatment of symptoms and signs of dry eye
  disease. Kala will receive an advance payment of
  60 million and be eligible for commercial-based
  sales milestone payments.
• Mark Iwicki, Chief Executive Officer and
  Chairman, Kala, said, The sale of EYSUVIS and
  INVELTYS is an important step as we execute on
  our strategic plan and pursue our mission of
  delivering innovative therapies that can address
  significant unmet needs in ophthalmology.
  (Source)
• New Drug Application (NDA) for Reproxalap by
  Aldeyra Therapeutics
• On 7th February 2023, Aldeyra Therapeutics
  announced the US Food and Drug Administrations
  (FDA) approval for the New Drug Application (NDA)
  for topical ocular Reporxalap. The company
  develops innovative therapies designed to treat
  immune-mediated diseases. The NDA is supplemented
  by previously announced efficacy and safety
  results from well-controlled and adequate
  clinical trials. These encompass data for ocular
  redness, Schirmer test 10 mm responder analysis,
  Schirmer test, ocular redness, and ocular dryness
  symptom score.
• Reporxalap is a first-in-class investigational
  new drug candidate for treating the symptoms and
  signs of dry eye disease. In dry eye disease
  patients, RASP (reactive aldehyde species) may
  facilitate changes in tear lipid composition,
  ocular redness, diminished tear production, and
  ocular inflammation.
• Accordingly, Reproxalap presents a differentiated
  and novel approach for treating the symptoms of
  dry eye disease.
• As stated by Todd C. Brady, MD, Ph.D., President
  and Chief Executive Officer

treatment of dry eye disease. (Source)
3

• New Drug Application (NDA) for CyclASol by
  Novaliq
• On 24th October 2022, Novaliq announced the US
  FDA approval of the New Drug Application (NDA)
  for CyclASol. It is a novel anti-inflammatory
  product for treating signs and symptoms of dry
  eye disease. It is preservative-free due to the
  novel carrier and contains no oils or
  surfactants. It offers additional clinical
  benefits like reduced visual disturbances and
  enhanced tolerability.
• According to Christian Roesky, Ph.D., CEO,
  Novaliq, This is an exciting time for
  ophthalmologists and optometrists and their
  patients as we are one step closer to address
  important needs and to better treat a serious
  ocular surface condition affecting millions of
  Americans. If approved, CyclASol would be a
  highly potent but comfortable anti-inflammatory
  therapy for patients with dry eye disease.
  (Source)
• Ongoing Research Development in Global Dry
  Disease Market
• As per several research investigations, dry eye
  is a lifestyle disease, and most of the
  population is vulnerable. Accordingly, there have
  been ongoing research and developments related to
  dry eye treatment and solutions. For instance,
  European Dry Eye Network was established in
  Europe under Horizon 2020. It is a platform for
  the training and career development of 10
  early-stage researchers (ESRs) in vision
  sciences. Such platforms are predicted to enhance
  research efforts for dry eye disease treatment,
  subsequently influencing the global dry eye
  disease
• market growth.
• FAQs
• Which country has lucrative prospects in the
  global dry eye disease market?
• A China has lucrative prospects in the global
  dry eye disease market.
• What are the risk factors of dry eye disease?
• A As per global experts, the non-modifiable risk
  factors of dry eye disease are age, connective
  tissue diseases, Meibomian Gland Dysfunction,
  Sjogren's syndrome, etc.